Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Georgiana Toma: From Cytoreduction to Vascular Protection in Essential Thrombocythemia
Georgiana Toma/X
Mar 21, 2026, 12:47

Georgiana Toma: From Cytoreduction to Vascular Protection in Essential Thrombocythemia

Georgiana Toma, Hematology resident at the University Emergency Hospital of Bucharest, shared a post on LinkedIn:

“To my colleagues in internal medicine and neurology

We have all managed patients with ‘controlled’ platelet counts who still suffer from devastating recurrent strokes or systemic thrombotic events.

The results of the SURPASS-ET study (published in The Lancet Haematology, 2026) change the conversation from simple cytoreduction to vascular protection and disease modification.

Ropeginterferon alfa-2b

For our patients resistant to hydroxyurea, the comparison between Ropeginterferon alfa-2b and Anagrelide reveals a massive shift in the safety-efficacy balance:

  • Vascular Risk: Complications (including cerebral infarction) were significantly lower with Ropeginterferon compared to Anagrelide.
  • Safety Profile: Half the rate of Serious Adverse Events (14 percent versus 30 percent).
  • Durable Response: A staggering 43 percent durable response at 12 months versus only 6 percent for anagrelide (p less than 0.0001).

Why this matters for your practice:

  1. Ropeginterferon significantly reduces the JAK2 (V617F) allelic burden. This suggests we can actually prevent the long-term transformation into Myelofibrosis or Acute Leukemia—something traditional therapies struggled to achieve.
  2. Neurological Protection: For Neurologists, this offers a potent tool to reduce the risk of cerebral infarction and hemorrhage in high-risk MPN patients.
  3. Fewer Side Effects: Better tolerability means higher compliance and fewer hospitalizations for drug-related complications.

The Bottom Line

We are moving toward a new standard where molecular remission is the goal.

By targeting the underlying biology of Myeloproliferative Neoplasms, we aren’t just treating a lab value; we are protecting our patients’ vascular future.”

Title: Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study

Authors: Ruben Mesa, Harinder Gill, Lei Zhang, Jie Jin, Keita Kirito, Norio Komatsu, Albert Qin, Zhijian Xiao, Tsewang Tashi, Kazuya Shimoda, Kohshi Ohishi, Suning Chen, Xuelan Zuo, Shuichi Shirane, Yu Hu, Sujiang Zhang, Yi Wang, Katsuto Takenaka, Michiko Ichii, Na Xu, Lee-Yung Shih, Ken-Hong Lim, Sung-Eun Lee, Sung Hwa Bae, Winnie Z Y Teo, Dawn Maze, Stephen T Oh, Prithviraj Bose, Toshiaki Sato, Zagrijtschuk, Sheena Lin, Weichung Joe Shih, John Mascarenhas, Lucia Masarova

Read the Full Article on The Lancet Haematology

Georgiana Toma: From Cytoreduction to Vascular Protection in Essential Thrombocythemia

 

Stay updated on all scientific advances with Hemostasis Today.

Albert Qin anagrelide Dawn Maze Essential Thrombocythemia Georgiana Toma Harinder Gill Health Hematology Hemostasis News Hemostasis Today Hydroxyurea JAK2 Jie Jin John Mascarenhas Katsuto Takenaka Kazuya Shimoda Keita Kirito Ken-Hong Lim Kohshi Ohishi Lee-Yung Shih Lei Zhang Lucia Masarova Medicine Michiko Ichii Na Xu Norio Komatsu Prithviraj Bose ropeginterferon alfa-2b Ruben Mesa Sheena Lin Shuichi Shirane Stephen T Oh Sujiang Zhang Sung Hwa Bae Sung-Eun Lee Suning Chen The Lancet Haematology Toshiaki Sato Tsewang Tashi V617F Weichung Joe Shih Winnie Z Y Teo Xuelan Zuo Yi Wang Yu Hu Zagrijtschuk Zhijian Xiao
NewsFeed